DDInter596 DDInter287
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022.
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elagolix
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) TCTN1
TCTN1 {u} (Gene) is upregulated by {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capmatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Jaundice cholestatic
Jaundice cholestatic {u} (Side Effect) is caused by {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capmatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) resembles Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) upregulates TCTN1 (Gene) and TCTN1 (Gene) is upregulated by Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Doxorubicin (Compound) causes Jaundice cholestatic (Side Effect) and Jaundice cholestatic (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib